Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEGCSF second level prophylactic use
- Development stage
- Unknown
- Lead developer
- Zhejiang Province Cancer Hospital
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
PEGCSF second level prophylactic use refers to the secondary prophylactic administration of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in patients undergoing myelosuppressive chemotherapy. In this regimen, PEG-rhG-CSF is administered subcutaneously 24 hours after chemotherapy in subsequent cycles only if the patient experienced febrile neutropenia (FN) or grade 4 neutropenia in a previous cycle. This approach is evaluated in clinical trials, such as those conducted by Zhejiang Cancer Hospital, to compare its efficacy, safety, and cost-effectiveness against primary (first-level) prophylaxis in breast cancer patients at medium-to-high risk of chemotherapy-induced neutropenia.
- Other names
- PEG-rhG-CSF secondary prophylaxissecondary prophylaxis of PEG-rhG-CSFsecondary prophylactic use of PEG-rhG-CSF
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on PEGCSF second level prophylactic use.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEGCSF second level prophylactic use.